<DOC>
	<DOCNO>NCT02974270</DOCNO>
	<brief_summary>Analysis body mass index Central Precocious Puberty patient treat leuprolide acetate</brief_summary>
	<brief_title>Analysis Body Mass Index Central Precocious Puberty Patients Treated With Leuprolide Acetate</brief_title>
	<detailed_description />
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Child diagnose CPP peakstimulated Lutenizing Hormone ( LH ) concentration 5 IU/liter initiation therapy 2 . Chronological age ( CA ) appearance pubertal change le 8 year girls less 9 year boys . 3 . Tanner stage â‰¥2 4 . Advanced bone age ( Bone Age/Chronological Age &gt; 1.1 ) 5 . Able sign write informed consent provide patient ' parent legal guardian prior studyrelated procedure 1 . Patient peripheral precocious puberty : extrapituitary secretion gonadotropin gonadotropinindependent gonadal adrenal sex steroid secretion 2 . Patient cerebral tumor require neurosurgery cerebral irradiation know chronic disease underlie medical condition 3 . Currently plan growth hormone treatment 4 . Previous GonadotropinReleasing Hormone agonist treatment 5 . Any patient opinion investigator participate study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>